- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
PRIMARY MALIGNANT MELANOMA OF THE FEMALE URETHRA: A CASE REPORT
-
- Suzuki Hiroaki
- Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
- Nakanishi Yasukazu
- Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
- Yoshino Koji
- Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
- Kataoka Madoka
- Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
- Fukushima Hiroshi
- Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
- Tobisu Kenichi
- Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
-
- Koga Fumitaka
- Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Bibliographic Information
- Other Title
-
- 女性尿道原発悪性黒色腫の一例
Search this article
Description
<p>We report a case of primary malignant melanoma (MM) of the female urethra. A 60-year-old female complained bleeding from the urethral meatus. MRI revealed a mass of 20 mm at the external urethral meatus. Pathological examination of transurethrally resected specimens revealed MM with stromal invasion. She underwent total urethrectomy plus cystostomy and sentinel lymph node biopsy. The tumor was pathologically confined in the specimen and no lymph node metastasis was found. She received interferone β as adjuvant therapy. However, she developed bilateral adrenal and pulmonary hilar lymph node metastases 1 year after urethrectomy. Although she started to receive nivolumab as salvage therapy, the disease progressed as well as development of interstitial pneumonia (IP) after four cycles. Following improvement of IP with steroid therapy, she started to receive ipilimumab, which resulted in the development of intolerable IP of grade 3. The patient finally died of MM 19 months after the initiation of treatment.</p>
Journal
-
- The Japanese Journal of Urology
-
The Japanese Journal of Urology 109 (2), 111-115, 2018-04-20
THE JAPANESE UROLOGICAL ASSOCIATION